Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
OBI Pharma, Inc
ClinicalTrials.gov Identifier:
NCT01516307
First received: January 19, 2012
Last updated: September 9, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: February 2017
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)